Obsessive-compulsive disorder (OCD) is an emerging indication for psilocybin therapy with a plausible mechanistic basis. OCD involves dysfunction in serotonin-driven circuits — the same pathways targeted by psilocybin's action at 5-HT2A receptors. Early studies at Yale and Johns Hopkins show significant symptom reduction after psilocybin sessions, even in patients who hadn't responded to SSRIs.
The hypothesis is that psilocybin's ability to temporarily disrupt rigid neural patterns allows patients to break free from the compulsive feedback loops characteristic of OCD. Multiple Phase 2 trials are now underway to test this mechanism in larger patient populations.
What clinical research has shown for OCD, with citations to the studies behind each finding
In a small 2006 safety study of 9 people with OCD, psilocybin produced marked reductions in obsessive-compulsive symptoms — 23% to 100% drops in symptom scores during one or more sessions. The study was small and uncontrolled; larger phase 2 trials are now underway to test the finding properly.
These summaries are for general education, not medical advice. Most psychedelic therapies remain investigational and are not yet approved — always consult a qualified clinician.
9 trials currently recruiting
Centre for Addiction and Mental Health
Yale University
Johns Hopkins University
Imperial College London
Brain and Cognition Discovery Foundation
Yale University